18438746. METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR simplified abstract (Regeneron Pharmaceuticals, Inc.)
Contents
- 1 METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Key Features and Innovation
- 1.6 Potential Applications
- 1.7 Problems Solved
- 1.8 Benefits
- 1.9 Commercial Applications
- 1.10 Prior Art
- 1.11 Frequently Updated Research
- 1.12 Questions about Cancer Pain Treatment
- 1.13 Original Abstract Submitted
METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR
Organization Name
Regeneron Pharmaceuticals, Inc.
Inventor(s)
Chieh-I Chen of Brooklyn NY (US)
Denise P. Bury-maynard of Bridgewater NJ (US)
Medha R. Sasane of Bridgewater NJ (US)
METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR - A simplified explanation of the abstract
This abstract first appeared for US patent application 18438746 titled 'METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR
Simplified Explanation
The patent application discusses methods for treating cancer pain by administering a PD-1 inhibitor to cancer patients, which can also reduce the need for analgesic therapy.
- Selecting cancer patients and giving them PD-1 inhibitors
- Reducing analgesic use in cancer patients by administering PD-1 inhibitors
- Potential tumor regression, pain reduction, and decreased analgesic therapy use
Key Features and Innovation
- Treatment of cancer pain with PD-1 inhibitors
- Reduction of analgesic use in cancer patients
- Potential for tumor regression and pain relief simultaneously
Potential Applications
The technology can be applied in the medical field for treating cancer patients suffering from pain and reducing their reliance on analgesic therapy.
Problems Solved
The technology addresses the challenges of managing cancer pain effectively and reducing the side effects and dependency associated with analgesic therapy.
Benefits
- Improved pain management for cancer patients
- Reduced need for analgesic therapy
- Potential for tumor regression
Commercial Applications
The technology has potential commercial applications in the pharmaceutical industry for developing new treatments for cancer pain management.
Prior Art
Readers can explore existing research on PD-1 inhibitors in cancer treatment and pain management to understand the background of this technology.
Frequently Updated Research
Researchers are continually studying the effectiveness of PD-1 inhibitors in cancer pain management and their impact on reducing analgesic use.
Questions about Cancer Pain Treatment
How do PD-1 inhibitors work in reducing cancer pain?
PD-1 inhibitors help the immune system recognize and attack cancer cells, potentially reducing tumor size and associated pain.
What are the potential side effects of using PD-1 inhibitors for cancer pain?
Common side effects may include fatigue, rash, and immune-related adverse events, which should be monitored closely during treatment.
Original Abstract Submitted
The present disclosure provides methods of treating or inhibiting cancer pain in a patient in need thereof, including selecting a patient with cancer, and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor. The present disclosure also provides methods of reducing analgesic use in a patient in need thereof, including selecting a patient with cancer, and administering to the patient a therapeutically effective amount of a PD-1 inhibitor, wherein the patient is being treated with background analgesic therapy prior to administration of the PD-1 inhibitor. In some embodiments, the disclosed methods concurrently lead to tumor regression, pain reduction, and reduced use of analgesic therapy.
